---
document_datetime: 2025-12-29 10:58:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lutetium-177lu-chloride-billev.html
document_name: lutetium-177lu-chloride-billev.html
version: success
processing_time: 0.1135684
conversion_datetime: 2025-12-31 02:28:31.158359
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lutetium (177Lu) chloride Billev (previously Illuzyce)

[RSS](/en/individual-human-medicine.xml/67601)

##### Authorised

This medicine is authorised for use in the European Union

lutetium (177Lu) chloride Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lutetium (177Lu) chloride Billev (previously Illuzyce)](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Lutetium ( 177 Lu) chloride Billev is a solution containing a radioactive form of lutetium ( 177 lu) that is used for radiolabelling other medicines. Radiolabelling is a technique where a substance is labelled with a radioactive compound. Once the substance is radiolabelled with Lutetium ( 177 Lu) chloride Billev, it then carries the radioactivity to where it is needed in the body (for example, the site of a tumour).

Lutetium ( 177 Lu) chloride Billev is used to radiolabel medicines that have been specifically developed for use with lutetium ( 177 lu) chloride.

Lutetium ( 177 Lu) chloride Billev contains the active substance lutetium ( 177 lu) chloride.

Expand section

Collapse section

## How is Lutetium (177Lu) chloride Billev used?

Lutetium ( 177 Lu) chloride Billev is only to be used by specialists who have experience in radiolabelling. Lutetium ( 177 Lu) chloride Billev is never given directly to a patient. Radiolabelling of a medicine takes place in a laboratory setting. The radiolabelled medicine is then given to the patient according to the instructions in that medicine's summary of product characteristics (SmPC).

## How does Lutetium (177Lu) chloride Billev work?

The active substance in Lutetium ( 177 Lu) chloride Billev , lutetium ( 177 lu) chloride, is a radioactive compound that emits mainly a type of radiation known as 'beta-minus', for treatment, and a small amount of gamma radiation, for imaging. When a medicine is radiolabelled with Lutetium ( 177 Lu) chloride Billev , the medicine will carry the radiation to the particular site or type of cell in the body that is targeted by the medicine

## What benefits of Lutetium (177Lu) chloride Billev have been shown in studies?

The company presented information from published clinical studies on the potential uses of Lutetium ( 177 Lu) chloride Billev . Some of the data presented showed the usefulness of 177 Lu in radiolabelling medicines for treating neuroendocrine tumors and prostate cancer, used together with imaging techniques to detect the site and spread of tumours.

## What are the risks associated with Lutetium (177Lu) chloride Billev?

The side effects with Lutetium ( 177 Lu) chloride Billev depend largely on the medicine it has been used to radiolabel and will be described in that medicine's package leaflet. Lutetium ( 177 Lu) chloride Billev itself is radioactive and so its use in radiolabelling may carry a risk of developing cancer and hereditary defects. The doctor will ensure that the risks linked to the radioactive exposure are lower than the risks from the disease itself.

The most common side effects (which may affect more than 1 in 10 people) are anaemia (low red blood cell counts), thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), lymphopenia (low levels of lymphocytes, a particular type of white blood cell), nausea (feeling sick), vomiting and hair loss.

Lutetium ( 177 Lu) chloride Billev must not be given directly to any patient. It must not be used in women who are known to be or may be pregnant, and when pregnancy has not been ruled out. For the full list of restrictions of Lutetium ( 177 Lu) chloride Billev , see the package leaflet.

Information on the restrictions on the use of medicines radiolabelled with Lutetium ( 177 Lu) chloride Billev can be found in the respective package leaflets.

## Why is Lutetium (177Lu) chloride Billev authorised in the EU?

The European Medicines Agency decided that Lutetium ( 177 Lu) chloride Billev 's benefits for radiolabelling medicines are greater than its risks and it can be authorised for use in the EU. Given the well-known risks linked to radiation exposure, the Agency concluded Lutetium ( 177 Lu) chloride Billev is only to be used if justified by the likely medical benefit.

## What measures are being taken to ensure the safe and effective use of Lutetium (177Lu) chloride Billev?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lutetium ( 177 Lu) chloride Billev have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Lutetium ( 177 Lu) chloride Billev are continuously monitored. Suspected side effects reported with Lutetium ( 177 Lu) chloride Billev are carefully evaluated and any necessary action taken to protect patients.

## Other information about Lutetium (177Lu) chloride Billev

Lutetium ( 177 Lu) chloride Billev received a marketing authorisation valid throughout the EU on 15 September 2022.

This overview was last updated in 12-2022.

Lutetium (177Lu) chloride Billev (previously Illuzyce) : EPAR - Medicine overview

Reference Number: EMEA/H/C/005859

English (EN) (186.18 KB - PDF)

**First published:** 21/09/2022

**Last updated:** 08/12/2022

[View](/en/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_en.pdf)

[Other languages (21)](#file-language-dropdown-760)

български (BG) (172.67 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/bg/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_bg.pdf)

español (ES) (159.32 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/es/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_es.pdf)

čeština (CS) (161.99 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/cs/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_cs.pdf)

dansk (DA) (158.78 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/da/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_da.pdf)

Deutsch (DE) (162.18 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/de/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_de.pdf)

eesti keel (ET) (126.64 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/et/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_et.pdf)

ελληνικά (EL) (171.55 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/el/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_el.pdf)

français (FR) (160.58 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/fr/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_fr.pdf)

hrvatski (HR) (297.26 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/hr/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_hr.pdf)

italiano (IT) (157.62 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/it/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (191.32 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/lv/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (161.22 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/lt/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_lt.pdf)

magyar (HU) (160.72 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/hu/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_hu.pdf)

Malti (MT) (205.46 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/mt/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_mt.pdf)

Nederlands (NL) (159.41 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/nl/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_nl.pdf)

polski (PL) (162.6 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/pl/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_pl.pdf)

português (PT) (161.04 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/pt/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_pt.pdf)

slovenčina (SK) (204.32 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/sk/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_sk.pdf)

slovenščina (SL) (159.57 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/sl/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_sl.pdf)

Suomi (FI) (203.48 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/fi/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_fi.pdf)

svenska (SV) (156.69 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/sv/documents/overview/lutetium-177lu-chloride-billev-previously-illuzyce-epar-medicine-overview_sv.pdf)

Illuzyce : EPAR - Risk Management Plan

English (EN) (375.56 KB - PDF)

**First published:** 07/06/2023

[View](/en/documents/rmp/illuzyce-epar-risk-management-plan_en.pdf)

## Product information

Lutetium (177Lu) chloride Billev : EPAR - Product Information

English (EN) (213.61 KB - PDF)

**First published:** 21/09/2022

**Last updated:** 29/11/2024

[View](/en/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-27)

български (BG) (343.07 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/bg/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_bg.pdf)

español (ES) (197.26 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/es/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_es.pdf)

čeština (CS) (305.2 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/cs/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_cs.pdf)

dansk (DA) (203.01 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/da/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_da.pdf)

Deutsch (DE) (209.02 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/de/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_de.pdf)

eesti keel (ET) (197.85 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/et/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_et.pdf)

ελληνικά (EL) (325.01 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/el/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_el.pdf)

français (FR) (201.8 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/fr/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_fr.pdf)

hrvatski (HR) (292.45 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/hr/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_hr.pdf)

íslenska (IS) (202.36 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/is/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_is.pdf)

italiano (IT) (197.18 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/it/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_it.pdf)

latviešu valoda (LV) (298.54 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/lv/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_lv.pdf)

lietuvių kalba (LT) (300.05 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/lt/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_lt.pdf)

magyar (HU) (300.38 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/hu/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_hu.pdf)

Malti (MT) (343.42 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/mt/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_mt.pdf)

Nederlands (NL) (221.46 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/nl/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_nl.pdf)

norsk (NO) (193.87 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/no/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_no.pdf)

polski (PL) (307.03 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/pl/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_pl.pdf)

português (PT) (203.53 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/pt/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_pt.pdf)

română (RO) (307.03 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/ro/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_ro.pdf)

slovenčina (SK) (314.12 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/sk/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_sk.pdf)

slovenščina (SL) (296.21 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/sl/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_sl.pdf)

Suomi (FI) (197.38 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/fi/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_fi.pdf)

svenska (SV) (201.05 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

29/11/2024

[View](/sv/documents/product-information/lutetium-177lu-chloride-billev-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0005/G 07/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lutetium (177Lu) chloride Billev (previously Illuzyce) : EPAR - All Authorised presentations

English (EN) (16.49 KB - PDF)

**First published:** 21/09/2022

**Last updated:** 08/12/2022

[View](/en/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-324)

български (BG) (39.31 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/bg/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.69 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/es/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_es.pdf)

čeština (CS) (33.02 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/cs/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (13.36 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/da/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.34 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/de/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.97 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/et/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (35.48 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/el/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_el.pdf)

français (FR) (15.07 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/fr/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (33.09 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/hr/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.84 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/is/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.95 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/it/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (35.71 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/lv/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (23.48 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/lt/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (32.1 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/hu/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.62 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/mt/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.81 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/nl/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.17 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/no/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_no.pdf)

polski (PL) (32.51 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/pl/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.54 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/pt/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.53 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/ro/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.68 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/sk/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.44 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/sl/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.08 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/fi/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.39 KB - PDF)

**First published:**

21/09/2022

**Last updated:**

08/12/2022

[View](/sv/documents/all-authorised-presentations/lutetium-177lu-chloride-billev-previously-illuzyce-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lutetium (177Lu) chloride Billev (previously Illuzyce) Active substance lutetium (177Lu) chloride International non-proprietary name (INN) or common name lutetium (177Lu) chloride Therapeutic area (MeSH) Radionuclide Imaging Anatomical therapeutic chemical (ATC) code V10X

### Pharmacotherapeutic group

Therapeutic radiopharmaceuticals

### Therapeutic indication

Lutetium ( 177 Lu) chloride Billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium ( 177 Lu) chloride.

## Authorisation details

EMA product number EMEA/H/C/005859 Marketing authorisation holder

Billev Pharma Aps

Slotsmarken 10

Opinion adopted 21/07/2022 Marketing authorisation issued 15/09/2022 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lutetium (177Lu) chloride Billev : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (152.8 KB - PDF)

**First published:** 08/12/2022

**Last updated:** 29/11/2024

[View](/en/documents/procedural-steps-after/lutetium-177lu-chloride-billev-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Illuzyce : EPAR - Public assessment report

Adopted

Reference Number: EMA/689220/2022

English (EN) (941.49 KB - PDF)

**First published:** 21/09/2022

[View](/en/documents/assessment-report/illuzyce-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Illuzyce

Adopted

Reference Number: EMA/CHMP/617852/2022

English (EN) (147.71 KB - PDF)

**First published:** 22/07/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-illuzyce_en.pdf)

#### News on Lutetium (177Lu) chloride Billev (previously Illuzyce)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

**This page was last updated on** 29/11/2024

## Share this page

[Back to top](#main-content)